• Q32 Bio reported positive Week 36 topline Phase 2a results for bempikibart in severe alopecia areata in the open-label SIGNAL-AA Part B trial.
• Primary endpoint met in the prespecified mITT analysis, with a 35.3% mean reduction in SALT score from baseline.
• SALT-20 response reached 40% in mITT (10/25) versus 30.3% in ITT (10/33), supporting efficacy in a broader enrolled population.
• Safety profile remained consistent with prior studies, with no new safety signals or treatment-related serious adverse events.
• Program strategy updated, with a registration-directed development plan targeted for the first half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Q32 Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607130659PR_NEWS_USPR_____NE02579) on July 13, 2026, and is solely responsible for the information contained therein.